Phase I study of DMP 840 in pediatric patients with refractory solid tumors.

J Thompson, C B Pratt, C F Stewart, L Avery, L Bowman, W C Zamboni, A Pappo

Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

Investigational new drugs 1998

filter terms:

The bis-naphthalimide DMP 840 has demonstrated high level antitumor activity in a number of preclinical models and has been evaluated in several Phase I studies in adults. We enrolled 10 patients with refractory pediatric solid tumors to this Phase I study of DMP 840 given intravenously by short infusion daily for 5 days. The most frequent and dose-limiting toxicity was myelosuppression. The maximum tolerated dose on this schedule was 8.6 mg/m2 daily for 5 days. One patient had a complete response; there were no measurable tumor responses among the remaining 9 patients.

Citation

J Thompson, C B Pratt, C F Stewart, L Avery, L Bowman, W C Zamboni, A Pappo. Phase I study of DMP 840 in pediatric patients with refractory solid tumors. Investigational new drugs. 1998;16(1):45-9